Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544423 | 0.88 | ELANE (0.35) | ALDH1A1ELANEPIM1MEN1KMT2A | |
| SCHEMBL543963 | 0.85 | PTPRC (0.34) | PTPRCMEN1MAPTKMT2A | |
| SCHEMBL544088 | 0.84 | ALDH1A1 (0.33) | ALDH1A1ELANEMEN1POLBKMT2A | |
| SCHEMBL543659 | 0.81 | ELANE (0.37) | ALDH1A1ELANETSHR | |
| SCHEMBL892564 | 0.80 | PDE4A (0.36) | ALDH1A1TSHR | |
| SCHEMBL544456 | 0.79 | PDE4A (0.36) | ALDH1A1TSHR | |
| SCHEMBL543845 | 0.78 | ELANE (0.34) | ALDH1A1ELANE | |
| Hydrochloric Acid SCHEMBL892604 | 0.77 | ELANE (0.33) | ALDH1A1ELANE | |
| SCHEMBL543598 | 0.74 | HSD17B10 (0.37) | ALDH1A1ELANEMEN1POLBMAPT | |
| SCHEMBL543994 | 0.74 | PTPN1 (0.35) | ALDH1A1ELANETSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388000-B1 | Neuroprotectant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2077836-B1 | AMYLOID BETA DEPOSITION INHIBITOR CONTAINING SPIRO-HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KK (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2388001-B1 | Age retardant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20140171452-A1 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2388002-B1 | Antidepressant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2013-03-13 | — | — | EP | disclosed |
| WO-2012094612-A1 | METHOD OF TREATING ESSENTIAL TREMOR | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-07-12 | — | — | WO | disclosed |
| WO-2012094615-A2 | USE OF CAV3.1 SELECTIVE T-TYPE CALCIUM CHANNEL ANTAGONISTS | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-07-12 | — | — | WO | disclosed |
| EP-2429522-A2 | METHOD OF DECREASING UBIQUITYLATED PROTEIN LEVELS | The Regents of the University of California Office of Technology Transfer (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2419100-A2 | METHOD OF DECREASING PRO-ADAM10 SECRETASE AND/OR BETA SECRETASE LEVELS | Green, Kim Nicholas (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100168135-A1 | Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2077835-A2 | AN ALZHEIMER'S DISEASE PROGRESSION INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2009-07-15 | — | — | EP | disclosed |
| EP-2077836-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2009-07-15 | — | — | EP | disclosed |
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2008047952-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047951-A2 | AN ALZHEIMER' S DISEASE PROGRESSION INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| EP-1219621-B1 | AZAINDOLIZINONE DERIVATIVES AND COGNITIVE ENHANCERS COMPRISING THE SAME AS EFFECTIVE COMPONENTS | ZENYAKU KOGYO KK (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6635652-B1 | Senile dementia and Alzheimer's disease | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-10-21 | — | — | US | disclosed |
| EP-1219621-A1 | AZAINDOLIZINONE DERIVATIVES AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, GRN | ALDH1A1 116/4885ELANE 2252/4885TP53 4076/4885 |
| US-20100168135-A1 | Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment | APP, APBA1, BACE1 | ALDH1A1 3405/4885ELANE 380/4885TP53 129/4885 |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, BDNF | ALDH1A1 159/4885ELANE 2190/4885TP53 4703/4885 |
| US-20140171452-A1 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | PSEN1, GAP43, PSEN2 | ALDH1A1 905/4885ELANE 2583/4885TP53 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.